Shanghai Haohai Biological Technology Dirección
Dirección controles de criterios 4/4
El CEO de Shanghai Haohai Biological Technology's es Jianying Wu , nombrado en Jul 2010, tiene una permanencia de 13.75 años. compensación anual total es CN¥1.72M, compuesta por 49.8% salario y 50.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.63% de las acciones de la empresa, por valor de HK$539.27M. La antigüedad media del equipo directivo y de la junta directiva es de 9.3 años y 10.5 años, respectivamente.
Información clave
Jianying Wu
Chief Executive Officer (CEO)
CN¥1.9m
Compensación total
| Porcentaje del salario del CEO | 44.9% |
| Permanencia del CEO | 13.9yrs |
| Participación del CEO | 3.4% |
| Permanencia media de la dirección | 9.5yrs |
| Promedio de permanencia en la Junta Directiva | 10.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?
Feb 23What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?
Feb 05
Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 21Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend
Jan 06We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Dec 22Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥432m |
| Dec 31 2023 | CN¥2m | n/a | CN¥416m |
| Sep 30 2023 | n/a | n/a | CN¥346m |
| Jun 30 2023 | n/a | n/a | CN¥315m |
| Mar 31 2023 | n/a | n/a | CN¥248m |
| Dec 31 2022 | CN¥2m | CN¥855k | CN¥180m |
| Sep 30 2022 | n/a | n/a | CN¥203m |
| Jun 30 2022 | n/a | n/a | CN¥192m |
| Mar 31 2022 | n/a | n/a | CN¥272m |
| Dec 31 2021 | CN¥1m | CN¥845k | CN¥352m |
| Sep 30 2021 | n/a | n/a | CN¥428m |
| Jun 30 2021 | n/a | n/a | CN¥434m |
| Mar 31 2021 | n/a | n/a | CN¥370m |
| Dec 31 2020 | CN¥1m | CN¥768k | CN¥230m |
| Sep 30 2020 | n/a | n/a | CN¥232m |
| Jun 30 2020 | n/a | n/a | CN¥216m |
| Mar 31 2020 | n/a | n/a | CN¥279m |
| Dec 31 2019 | CN¥2m | CN¥742k | CN¥371m |
| Sep 30 2019 | n/a | n/a | CN¥353m |
| Jun 30 2019 | n/a | n/a | CN¥386m |
| Mar 31 2019 | n/a | n/a | CN¥375m |
| Dec 31 2018 | CN¥1m | CN¥712k | CN¥415m |
| Sep 30 2018 | n/a | n/a | CN¥411m |
| Jun 30 2018 | n/a | n/a | CN¥408m |
| Mar 31 2018 | n/a | n/a | CN¥390m |
| Dec 31 2017 | CN¥1m | CN¥583k | CN¥372m |
Compensación vs. Mercado: La compensación total de Jianying($USD237.19K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD552.33K).
Compensación vs. Ingresos: La compensación de Jianying ha sido consistente con los resultados de la empresa en el último año.
CEO
Jianying Wu (60 yo)
13.9yrs
Permanencia
CN¥1,904,800
Compensación
Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 13.9yrs | CN¥1.89m | 3.33% CN¥ 490.8m | |
| GM & Executive Director | 13.9yrs | CN¥1.90m | 3.37% CN¥ 495.9m | |
| CFO & Executive Director | 7.5yrs | CN¥1.45m | 0.036% CN¥ 5.2m | |
| Executive Director | 9.5yrs | CN¥1.26m | 0.24% CN¥ 34.7m | |
| Joint Company Secretary | 4.5yrs | CN¥868.70k | 0.0040% CN¥ 595.2k | |
| Deputy General Manager | 9.8yrs | CN¥912.50k | 0.011% CN¥ 1.6m | |
| Joint Company Secretary | 9.6yrs | sin datos | sin datos |
9.5yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 6826 es experimentado (9.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 13.9yrs | CN¥1.89m | 3.33% CN¥ 490.8m | |
| GM & Executive Director | 13.9yrs | CN¥1.90m | 3.37% CN¥ 495.9m | |
| CFO & Executive Director | 7.3yrs | CN¥1.45m | 0.036% CN¥ 5.2m | |
| Executive Director | 13.9yrs | CN¥1.26m | 0.24% CN¥ 34.7m | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Non Executive Director | 13.9yrs | sin datos | 43.26% CN¥ 6.4b | |
| Non-Executive Director | 13.9yrs | CN¥150.00k | 1.11% CN¥ 163.4m | |
| Chairman of the Supervisory Committee | 13.9yrs | sin datos | 1.11% CN¥ 163.4m | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | sin datos | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | sin datos | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | sin datos | |
| Independent Non-Executive Director | 4yrs | CN¥150.00k | sin datos |
10.6yrs
Permanencia media
52.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de 6826 son experimentados ( 10.5 años antigüedad media).